News for Marinus Pharmaceuticals Stock (MRNS)

Investigation Into Allegations Against Marinus Pharmaceuticals Inc Is Initiated By The Schall Law Firm And Investors With Losses Are Encouraged To Contact

Accesswire • 06/19/24

The Schall Law Firm Begins Probe Into Claims Against Marinus Pharmaceuticals Inc And Urges Affected Investors To Connect

Accesswire • 06/18/24

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)

Business Wire • 06/18/24

MRNS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors Can Join the Class Action Lawsuit

Accesswire • 06/18/24

The Schall Law Firm Begins Inquiry Into Claims Against Marinus Pharmaceuticals, Inc. And Invites Investors Who Have Suffered Losses To Establish Contact

Accesswire • 06/18/24

The Schall Law Firm Initiates Investigation Into Allegations Against Marinus Pharmaceuticals Inc And Encourages Investors Who Have Incurred Losses To Reach Out

Accesswire • 06/18/24

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors

Business Wire • 06/17/24

The Schall Law Firm Initiates Investigation Into Allegations Against Marinus Pharmaceuticals, Inc. And Encourages Investors Who Have Incurred Losses To Reach Out

Accesswire • 06/17/24

Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients

Benzinga • 06/17/24

MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc.

GlobeNewsWire • 06/17/24

Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus

Business Wire • 06/17/24

MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire • 06/16/24

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS

GlobeNewsWire • 06/16/24

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors

Business Wire • 06/14/24

Marinus Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Their Rights in Connection with the MRNS Class Action Lawsuit

Business Wire • 06/14/24

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors

Business Wire • 06/13/24

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors

Business Wire • 06/13/24

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors

Business Wire • 06/13/24

Investigation Into Claims Against Marinus Pharmaceuticals, Inc. Is Initiated By The Schall Law Firm And Investors Who Have Suffered Losses Are Encouraged To Make Contact

Accesswire • 06/12/24

The Law Offices of Frank R. Cruz Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors

Business Wire • 06/12/24

The Schall Law Firm Initiates Investigation Into Claims Against Marinus Pharmaceuticals, Inc. And Encourages Investors Who Have Incurred Losses To Reach Out

Accesswire • 06/11/24

The Schall Law Firm Starts Probe Into Claims Against Marinus Pharmaceuticals, Inc. And Invites Investors Who Have Suffered Losses To Make Contact

Accesswire • 06/11/24

MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Accesswire • 06/11/24

MRNS Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Class Action Against Marinus Pharmaceuticals, Inc.

GlobeNewsWire • 06/11/24

MARINUS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

GlobeNewsWire • 06/11/24